Cargando…

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition....

Descripción completa

Detalles Bibliográficos
Autores principales:	Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986340/ https://www.ncbi.nlm.nih.gov/pubmed/27532025 http://dx.doi.org/10.1186/s40425-016-0152-y

Ejemplares similares

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
por: Brunner-Weinzierl, Monika C., et al.
Publicado: (2018)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Emergent immunotherapy approaches for brain metastases
por: Wang, Jianbo, et al.
Publicado: (2021)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

Cardiotoxicity of Contemporary Anticancer Immunotherapy
por: Dal’bo, Natalie, et al.
Publicado: (2020)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review
por: Miller, Peter L., et al.
Publicado: (2020)

Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4
por: Jiang, Chunjuan, et al.
Publicado: (2021)

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2014)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance
por: Rodriguez, B. Leticia, et al.
Publicado: (2023)

The broad spectrum of cardiotoxicities from immunotherapies
por: Iengo, Martina, et al.
Publicado: (2023)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
por: Lambertini, Matteo, et al.
Publicado: (2019)

Correlation coefficients of three self-perceived orthodontic treatment need indices
por: Eslamipour, Faezeh, et al.
Publicado: (2017)

Combination immunotherapy: a road map
por: Ott, Patrick A., et al.
Publicado: (2017)

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment
por: Horton, Brendan, et al.
Publicado: (2015)

Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency
por: Watson, Leisa Rebecca, et al.
Publicado: (2018)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2016)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study
por: Zhao, Xiaoqin, et al.
Publicado: (2018)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2017)

Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV(+) oral cancer
por: Dorta-Estremera, Stephanie, et al.
Publicado: (2019)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_feb6em0oe3emvo3behbkll7m2b